With support from ScreeninC, Fernandez, Hijmans and colleagues concluded two whole genome CRISPR knock-out screens and one whole-genome CRISPR activation screen. These screens provided new insight into MEK inhibitor (MEKi) resistance in low-grade serous ovarian cancer and a novel, candidate treatment strategy consisting of MEKi and trametinib.

The results of this project have been published in Molecular Cancer Therapeutics.